Edition:
United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

132.80EUR
4:39pm BST
Change (% chg)

€1.50 (+1.14%)
Prev Close
€131.30
Open
€131.90
Day's High
€133.70
Day's Low
€131.50
Volume
65,667
Avg. Vol
106,755
52-wk High
€133.70
52-wk Low
€54.30

Allen, Debbie 

Dr. Debbie Allen serves as Senior Director, Business Development at argenx SE. Debbie has been active in the antibody engineering field since the 1980s. She brings to arGEN-X more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. She established her Business Development career at Cambridge Antibody Technology (now MedImmune), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the monoclonal antibody drug BENLYSTA (belimumab), now approved for the treatment of systemic lupus erythematosus. Prior to joining arGEN-X, Debbie acted for eight years as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support. Dr. Allen holds an B. Sc. in cellular pathology from the University of Bristol and a Ph. D. in viral oncology from the University of London.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --